Investing.com - Lantern Pharma (NASDAQ: LTRN) reported third quarter EPS of $-0.29, $0.19 better than the analyst estimate of $-0.48. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Lantern Pharma's stock price closed at $2.80. It is down -42.86% in the last 3 months and down -34.73% in the last 12 months.
Lantern Pharma saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Lantern Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Lantern Pharma's Financial Health score is "fair performance".
Check out Lantern Pharma's recent earnings performance, and Lantern Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar